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Abstract
Background & Objectives: Intravenous iron supplementation is widespread in the hemodialysis population, but
there is uncertainty about the safest dosing strategy. We compared the safety of different intravenous iron dosing
practices on the risk of adverse cardiovascular outcomes in a large population of hemodialysis patients.
Design settings, participants, & measurements: A retrospective cohort was created from the clinical database of a
large dialysis provider (years 2004-2008) merged with administrative data from the United States Renal Data
System. Dosing comparisons were (1) bolus (consecutive doses ≥ 100 mg exceeding 600 mg during one month)
versus maintenance (all other iron doses during the month); and (2) high (> 200 mg over 1 month) versus low dose
(≤ 200 mg over 1 month). We established a 6-month baseline period (to identify potential confounders and effect
modifiers), a one-month iron exposure period, and a three-month follow-up period. Outcomes were myocardial
infarction, stroke, and death from cardiovascular disease.
Results: 117,050 patients contributed 776,203 unique iron exposure/follow-up periods. After adjustment, we found
no significant associations of bolus dose versus maintenance, hazards ratio for composite outcome, 1.03 (95% C.I.
0.99, 1.07), or high dose versus low dose intravenous iron, hazards ratio for composite outcome, 0.99 (95% C.I. 0.96,
1.03). There were no consistent associations of either high or bolus dose versus low or maintenance respectively
among pre-specified subgroups.
Conclusions: Strategies favoring large doses of intravenous iron were not associated with increased short-term
cardiovascular morbidity and mortality. Investigation of the long-term safety of the various intravenous iron
supplementation strategies may still be warranted.
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Introduction
Erythropoiesis stimulating agents (ESAs) and intravenous
(IV) iron have been used in combination to manage anemia in
the dialysis population for many years. Clinical trials providing
new safety information about ESAs [1-3] and the
implementation of capitated payments for dialysis services [4]
have led to a relative shift away from ESA use. The use of IV
iron for the management of anemia during the same period has
grown [5].
Yet, little is known about the safety of IV iron. In
contemporary practice, intravenous iron administration varies
among clinicians and dialysis units [6,7]. Some providers
administer large sequential doses of approximately 1 gram per
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month and others, aliquots of 50-100 mg spaced over weeks.
Any single patient may be exposed to either of these dosing
strategies during his or her time receiving hemodialysis.
While the optimal dosing regimen for IV iron remains
unknown, biological mechanisms suggest that the sub-optimal
use of iron could lead to adverse clinical events [8]. Free iron is
a potent oxidizing agent that can catalyze the formation of
highly reactive oxygen species [9,10]. These highly reactive
oxygen species could give rise to lipid radicals, which may lead
to endothelial dysfunction [11] and atherogenesis [12], possibly
increasing the risk of cardiovascular events in a population
already known to have a high burden of cardiovascular disease
[13].
We therefore conducted a large-scale retrospective
observational study using data from a large national dialysis
provider linked with the United States Renal Data System
(USRDS). Our goal was to examine the comparative short-term
cardiovascular safety of common dosing strategies of IV iron in
a cohort of contemporary patients receiving hemodialysis, and
among pre-specified subgroups of patients.
Materials and Methods
Data Sources
The data used for this study came from the clinical research
database of a large dialysis provider and the USRDS. The
dialysis provider owns and manages over 1,500 outpatient
dialysis facilities located throughout the United States in urban,
rural, and suburban areas. Their clinical database captures
detailed clinical, laboratory, and treatment data on patients
receiving care at all of their dialysis units. All data are collected
using standardized electronic health record systems. For this
study, we used the clinical data to obtain detailed information
on IV iron dosing, epoetin alfa (EPO) use and dosing, clinical
laboratory values (e.g., hemoglobin, transferrin saturation
(TSAT), serum ferritin), and current vascular access. The
USRDS is a national data system funded by the National
Institutes of Diabetes and Digestive and Kidney Diseases that
collects, analyzes, and distributes information about the
treatment of end stage renal disease (ESRD). The USRDS
data includes data from the Medical Evidence Report Form, the
Medicare Enrollment database, the ESRD Death Notification
Form, and the standard analytic files, which contain final action
claims data [14].
We examined 5 years of data (2004 - 2008) from the clinical
database to identify the cohort. These data were merged with
data from the USRDS to obtain information on demographic
characteristics, health care use (e.g., hospitalizations,
outpatient care), and additional clinical characteristics (e.g.,
comorbidities).
Study Design
We utilized a retrospective cohort design in which we
established a 6-month baseline period (to identify potential
confounders and effect modifiers), a one-month iron exposure
period, and a three-month follow-up period (see Figure 1). The
index date of the exposure period was anchored on the day of
a laboratory assessment of TSAT, because this information is
used to guide subsequent iron administration.
Figure 1.  Study Design.  
doi: 10.1371/journal.pone.0078930.g001
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Cohort Identification
Figure 2 depicts the creation of our sample. Following the
merge of the clinical and USRDS data, we first identified
center-based, hemodialysis patients who had at least one
TSAT measurement after undergoing dialysis for at least 9
months. The 9-month period accounted for the 6-month
baseline period and an additional 3 months from the start of
dialysis to allow for stability in the claims processing by the
Centers for Medicare and Medicaid Services (CMS) [14].
Individuals with polycystic kidney disease were then excluded
because of the low use of ESA’s or IV iron. Eligible patients
could contribute more than one TSAT measurement. TSAT
measurements were eligible if they occurred between January
30, 2004 (to allow assessment of lab values and medications in
the last month of baseline) and November 30, 2008 (to allow
for the 1-month exposure period and at least one day of follow-
up).
Measurements of TSAT were excluded if 1) iron dextran or
both ferric gluconate and iron sucrose were administered
during the exposure period; 2) fewer than 120 days of the 180-
Figure 2.  Cohort Identification.  
doi: 10.1371/journal.pone.0078930.g002
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day baseline period were covered by Part A claims (which
include dialysis claims), suggesting incomplete data; and 3)
there were fewer than 9 dialysis sessions in the last month of
baseline or the exposure period. We also excluded TSAT
records with missing covariate information and TSAT
measurements that occurred in the follow-up period of a prior
eligible TSAT. The exposure assessment period began the day
after the qualifying TSAT measurement.
Study Variables
Outcomes.  We examined four cardiovascular outcomes:
death attributed to cardiovascular disease, hospitalization for
myocardial infarction (MI), hospitalization for stroke, and a
combined/composite outcome of any one of these three. These
outcomes were determined by examining the CMS inpatient
and outpatient claims and death notification data. The specific
definitions for each outcome are presented in Table S1 in File
S1.
Exposures.  The primary exposures of interest were: (1)
high dose versus low dose iron administration and (2) bolus
versus maintenance dosing. Based on the distribution of IV iron
dosing, we defined high dose as > 200 mg of IV iron in the one
month exposure period. Low dose was defined as 1-200 mg of
IV iron. We also created a no iron category for individuals who
did not receive any IV iron during the 1-month exposure period.
For the 2-week and 1-week exposure periods, high doses were
greater than 125 mg and 75 mg, respectively.
A month was classified as a bolus month if it contained
administrations of iron on consecutive dialysis sessions of at
least 100 mg.  We also classified a month as a bolus month if it
contained two or more administrations of iron > 100 mg that
had the potential to exceed 600mg within 30 days based on
spacing between the doses in the sequence.  For example, two
consecutive iron doses of 200 mg each, within 10 days, would
qualify as a bolus dose according to our definition. Months that
had no bolus dosing patterns were classified as “maintenance
months”. We also included a no iron category.
Confounders.  We included several covariates in our cohort
analyses. Descriptions of the covariates and the manner in
which they were defined in our models are presented in Table
S2 in File S1. Covariates included demographic characteristics
(e.g., age, sex, race, Medicaid eligibility, census region, year),
clinical characteristics (e.g., cause of ESRD, vintage, body
mass index (BMI), type of vascular access, number of hospital
days), laboratory and anemia management variables (e.g.
baseline hemoglobin, ferritin, TSAT, iron dose, EPO dose,
albumin, receipt of a blood transfusion, EPO dose during
exposure period), and several comorbidity measures based on
the Elixhauser classification [15], and content expertise of the
investigative team. Due to the extensive list of comorbidities,
we selected ones to include in a parsimonious model and ones
to add during sensitivity analyses.
Statistical Analysis
To assess the relation between iron dosing practices and
adverse outcomes, we used Cox proportional hazards
regression analyses to estimate hazard ratios (HR) and a
semiparametric additive risks model to estimate risk differences
(RD), all accompanied by their respective 95% confidence
intervals (CI) [16]. Individuals were censored at death (for the
hospitalization outcomes), loss to follow-up, receipt of a kidney
transplant, or administratively at the end of available data. We
first estimated an unadjusted HR (e.g. high versus low dose)
for each outcome and then a multivariable-adjusted HR that
included age, sex, race, BMI, EPO dose during baseline and
the exposure period, baseline hemoglobin, baseline ferritin,
index TSAT, current use of a catheter vascular access, years
on dialysis, serum albumin, number of days in hospital, any
infection in last month, and history of the following in the last
six months: diabetes, stroke, MI, pneumonia, vascular access
infection, sepsis, chronic obstructive pulmonary disease,
cancer, and gastrointestinal bleeding.
We also conducted these analyses within several subgroups
that were defined a priori based on demographic and clinical
characteristics as defined in Table S3 in File S1. Individuals
were categorized based on race, vintage, catheter use, history
of infection in last month of baseline, TSAT levels at baseline,
Ferritin levels at baseline, TSAT*Ferritin combinations (e.g.,
low TSAT and high ferritin) at baseline, albumin levels at
baseline, and hemoglobin levels at baseline.
Sensitivity Analyses.  To assess the robustness of the
results dependent on shorter exposure and/or follow-up
periods, we repeated the analyses on other cohorts: i.e., two
week exposure, six week follow-up; one week exposure, six
week follow-up; one month exposure, six week follow-up. To
assess the addition of other potentially relevant covariates, we
conducted a sensitivity analysis where we added additional
covariates: reported cause of ESRD, year, region, Medicaid
eligibility, and a number of additional comorbidities (Table S2 in
File S1).
The UNC Institutional Review Board approved this study.
The Institutional Review Board did not deem it necessary to
obtain written consent for the use of de-identified patient
information from the dialysis registry.
Results
A total of 117,050 patients met the study entry requirements
and contributed 776,203 unique iron exposure/follow-up
periods for comparisons of outcomes among dosing strategies,
Figure 2. The patient characteristics of the primary cohort
stratified by dosing pattern are presented in Table 1. The
greatest number of exposure periods corresponded to our
definition of maintenance iron dosing, followed by no iron (non-
users), low dose, high dose, and bolus. The groups had
generally similar demographic and medical characteristics with
some notable exceptions. For example, the prevalence of
dialysis catheters was higher in the bolus and high dose iron
groups than in the maintenance or low dose groups. Mean
hospital days in the past month were also higher for the bolus
and high dose iron groups. The prevalence of comorbid
conditions, both cardiovascular and other, was also higher in
the bolus and high dose IV iron groups than in the other
groups.
Tables 2 shows the results for the high versus low dose
comparison with respect to the cardiovascular outcomes.
Comparative Safety of Intravenous Iron
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e78930
Compared to low dose, high dose IV iron was associated with
an increased risk of cardiovascular events, including acute
myocardial infarct and stroke, and cardiovascular death in
unadjusted models. However, after adjustment for several
covariates, there was no significant association, assessed
either by HR, or RD.
Comparison of bolus and maintenance dosing revealed
similar associations to the high and low dose comparison. The
unadjusted HR demonstrated an increased risk of all measured
cardiovascular outcomes with bolus dosing, Table 3. With
adjustment, however, the HR and RD were strongly attenuated
towards the null.
Results of the subgroup analyses are presented in Tables S4
and S5 in File S1 for the high versus low dose and bolus
versus maintenance dosing comparisons, respectively. There
were no consistent trends seen, though in the bolus versus
maintenance comparison, individuals with high ferritin (500-800
mcg/L) and low TSAT (<25%) that were administered a bolus
dose of iron had increased risks of cardiovascular death, and
the composite outcome of death, myocardial infarction, or
stroke.
Sensitivity analyses using additional covariates, and with
differing exposure and follow up periods, did not change the
point estimates of the fully adjusted models as seen in either
Table 2 or 3. These data are not shown. Furthermore, we
Table 1. Patient Characteristics at Baseline, by Exposure Group (N = 776,203).
Characteristic High (24.0%) Low (37.8%) Bolus (12.6%) Maintenance (49.2%) Non-user (38.2%)
Mean (SD) Age, y 60.8 (15.0) 61.5 (15.0) 60.6 (15.1) 61.4 (14.9) 61.4 (14.9)
Female (%) 45.4 45.4 46.1 45.3 46.3
Race (%)      
White 49.2 49.1 47.5 49.6 47.9
Black 45.8 44.5 47.8 44.3 45.0
Medicaid (%) 50.9 51.0 51.9 50.7 51.6
Region (%)      
Midwest 18.0 16.8 17.4 17.2 16.2
Northeast 12.3 12.7 11.9 12.7 12.3
South 51.9 47.1 55.3 47.3 50.4
West 17.2 22.9 14.9 22.2 20.7
ESRD Reason (%)      
Diabetes 46.4 44.7 45.8 45.3 43.3
Glomerulonephritis 12.0 12.6 12.0 12.5 13.1
Hypertension 30.4 31.1 30.8 30.9 31.3
Mean (SD) Vintage, y 4.0 (4.1) 4.3 (4.4) 4.0 (4.1) 4.3 (4.3) 4.8 (4.6)
Mean (SD) BMI 27.4 (7.1) 27.3 (6.8) 27.1 (7.0) 27.4 (6.9) 26.6 (6.6)
Catheter (%) 23.8 21.8 25.5 21.8 20.4
Blood transfusion (%) 8.5 4.9 10.3 5.3 6.2
Hospital Days*, mean (sd) 0.8 (2.1) 0.5 (1.7) 1.0 (2.3) 0.5 (1.7) 0.5 (1.8)
Vascular access 13.4 9.7 15.0 10.1 8.9
Diabetes 56.6 52.1 57.1 53.0 50.9
Ischemic stroke 12.1 10.0 13.1 10.2 10.3
Myocardial infarction 4.2 2.9 4.6 3.1 3.1
COPD, Asthma 20.8 16.5 22.2 17.2 16.0
Cancer 9.2 8.1 9.8 8.2 8.4
Gasterointestinal bleeding 6.4 3.9 7.7 4.2 3.9
Labs and Medications, mean (sd)      
Index TSAT, % 24.7 (10.5) 30.4 (11.4) 22.4 (10.6) 29.7 (11.1) 35.0 (15.9)
Ferritin, mcg/L 489 (314) 536 (309) 481 (358) 527 (298) 766 (514)
Hemoglobin, g/dL 12.1 (1.4) 12.3 (1.2) 11.9 (1.5) 12.3 (1.2) 12.2 (1.3)
Albumin, g/dL 3.8 (0.4) 3.9 (0.4) 3.8 (0.4) 3.9 (0.4) 3.9 (0.4)
Baseline EPO, 1,000 units/mo. 112 (103) 78 (82) 127 (110) 82 (84) 70 (81)
Concurrent EPO, 1,000 units/mo. 107 (103) 76 (81) 123 (110) 79 (84) 74 (84)
Iron during baseline period, mg 331 (312) 189 (205) 354 (397) 216 (204) 89.0 (225.6)
Iron during exposure period, mg 538 (316) 135 (54) 689 (371) 190 (114) 0.0 (0.0)
ESRD= end stage renal disease, COPD= chronic obstructive pulmonary disease. * Hospital Days in previous month.
For the Bolus versus Maintenance groups, all variables were different at a significance level of p < 0.001, except for ESRD Reason (p=0.02).For High versus Low dose
groups, all variables were different at a significance level of p< 0.00, except for frequency of female (p=0.97), and frequency of Medicaid (p=0.84).
doi: 10.1371/journal.pone.0078930.t001
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observed no increase in risk of the outcomes under study
among recipients of maintenance iron dosing compared to non-
users of IV iron.
Discussion
In this cohort study of a representative group of adult
hemodialysis patients, we have examined the comparative
safety of several IV iron supplementation strategies on short-
term cardiovascular morbidity and mortality. To our knowledge,
this is the largest and certainly most contemporary study to
directly examine the comparative cardiovascular safety of
common IV iron dosing strategies, which are used throughout
many parts of the world, including the United States, Europe,
and Japan [17,18]. Our data show that larger doses of
intravenous iron are not associated with cardiovascular
morbidity or mortality compared to relatively smaller doses.
Furthermore, among the various pre-specified subgroups of
patients, there were no consistent differences in cardiovascular
events or mortality between patients receiving the various
dosing strategies.
There has been longstanding concern about the potential
adverse cardiovascular effects of intravenous iron. Ferric iron
(Fe3+) is reduced to ferrous iron (Fe2+) by leukocyte generated
superoxide dismutase [19]. Ferrous iron leads to the generation
of the reactive oxygen species, hydroxyl radical, known to
damage membrane lipids, oxidize low-density lipoprotein, and
promote atherogenesis [20]. It is believed that most
intravenous iron formulations, including ferric gluconate and
iron sucrose, release bioactive iron [8], especially if given
Table 3. Hazard Ratios and Risk Differences Comparing













































0.90 (-3.2, 4.7) 3.7 (-2.4, 9.9)
* Adjusted analyses controlled for the following variables at baseline: age; race;
sex; vintage; number of hospital days in last month; history of infection in last
month; body mass index; most recent vascular access, hemoglobin; ferritin; index
transferrin saturation; iron dose; albumin level; epoetin alfa dose; history in last 6
months of pneumonia, sepsis, vascular access infection, diabetes, stroke,
myocardial infarction, chronic obstructive lung disease, cancer, gastrointestinal
bleeding; and epoetin alfa dose during exposure. N=776,203
doi: 10.1371/journal.pone.0078930.t003
rapidly enough to oversaturate receptors [21]. Indeed, studies
with relatively small numbers of patients have suggested that
intravenous iron use is associated with an important clinical
pre-cursor of systemic atherosclerosis [22,23]; both studies, of
60 patients each, demonstrated a significant association of
total intravenous iron exposure with carotid intimal media
thickness.
Larger epidemiological studies however have not been able
to translate the association of intravenous iron exposure with
pre-clinical disease into more robust clinical outcomes. For
example, Feldman and colleagues examined the effect of IV
iron administration and mortality in a cohort of over 32,000
dialysis patients, and found no association of cumulative dose
of IV iron with mortality [24]. A second study of over 58,000
patients by Kalantar-Zadeh and colleagues also did not find an
association of iron dose with mortality, either all cause or
cardiovascular mortality [25]. Rather, the administration of up to
400 mg was associated with improved survival overall, and
among many relevant subgroups. At doses greater than 400
mg, there was a trend towards increased mortality. Our results
complement and extend these previous studies. Like them, we
did not find a consistent or meaningful association of IV iron
with cardiovascular morbidity or mortality. The richness of the
current data allowed us to examine clinically applicable dosing
patterns, rather than merely cumulative doses. Furthermore,
we were able to study specific outcomes related to
cardiovascular morbidity, including hospitalization for stroke
and myocardial infarction rather than just all-cause mortality.
Finally, a particular strength of our study (and in contrast to
previous studies), we had both patient-level electronic health
Table 2. Hazard Ratios and Risk Differences Comparing













































0.05 (-3.4, 3.5) -1.6 (-7.1, 3.9)
* Adjusted analyses controlled for the following variables at baseline: age; race;
sex; vintage; number of hospital days in last month; history of infection in last
month; body mass index; most recent vascular access, hemoglobin; ferritin; index
transferrin saturation; iron dose; albumin level; epoetin alfa dose; history in last 6
months of pneumonia, sepsis, vascular access infection, diabetes, stroke,
myocardial infarction, chronic obstructive pulmonary disease, cancer,
gastrointestinal bleeding; and epoetin alfa dose during exposure. N=776,203
doi: 10.1371/journal.pone.0078930.t002
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records information from the dialysis provider and claims data
from the public payer providing comprehensive and uniform
insurance to these patients.
The study should be interpreted in the context of the
following limitations. First, since we focused on events during a
3-month period, examination of long-term effects of IV iron on
cardiovascular events are not possible in this study. Yet, the
focus on short-term safety minimizes common sources of bias
in non-experimental studies with longitudinal exposures,
including time-varying confounding, selection bias, and
immortal person-time bias. This design improves the validity of
the exposure being related to the outcome. Future analyses,
perhaps using a marginal structural model [26], may be better
suited to determine the long-term safety of IV iron.
Second, the study was non-experimental in design, and,
therefore, could have been confounded by unobserved
differences between patient groups. There was an increased
prevalence of observed comorbidities among patients receiving
either high or bolus dosing of iron. This would theoretically bias
the association away from the null hypothesis and towards an
observed association with the higher doses of IV iron. The rich
clinical and administrative data found in the study allowed for
adjustment for important clinical and laboratory variables, and
in fact, there was no observed association of cardiovascular
morbidity and mortality.
The lack of an adverse cardiovascular safety signal should
not be interpreted as an unmitigated endorsement for the use
of large doses of IV iron. In an era of capitated payments for
dialysis services, black box warnings for ESA use, and
dynamic Quality Incentive Program performance measures
[4,27,28] there may be strong incentives for the use of large
doses of iron to manage anemia. Yet, another broad category
of adverse events, infectious complications from the
administration of intravenous iron, remains an unresolved issue
that requires additional investigation [29-32]. Furthermore, a
study on the effectiveness of larger doses of IV iron suggested
only a marginal benefit on anemia parameters such as
hemoglobin and EPO dose, compared to smaller doses of iron
[33]. Thus, until additional evidence is available, the prudent
choice may be moderation in the use of IV iron for the
management of anemia in hemodialysis patients [34,35].
In summary, large doses of IV iron supplementation were not
associated with short-term cardiovascular morbidity or mortality
in a contemporary cohort of hemodialysis patients. However,
additional safety concerns of IV iron administration, including
potential infectious complications and long-term cardiovascular
safety warrant further scrutiny. Ultimately, a controlled clinical
trial comparing intravenous iron dosing strategies may be
necessary to determine an approach that optimizes benefit and
minimizes risk to patients.
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